Hence, further studies and trials are needed to identify FGF21 and its mutations' roles in NAFLD and NASH development and also FGF21 analogs' effectiveness in NAFLD and NASH treatment. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.